ABCL AbCellera Biologics Inc.
ABCL AbCellera Biologics Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $3.52 · VWAP $6.45 · +83.0% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster
Coverage
1 related campaign
ABCL Price Structure
Loading timeframes…
Peers
Every watchlist ABCL belongs to, members best 30-day change first — ABCL highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
Reported the quarter ending 2026-06-30: revenue $4M, diluted EPS -$0.18, net income -$55M (SEC filing, revenue corroborated by the desk's provider cache). Across the print the stock moved +7.2% (close before → first close after).
full note →Against street estimates
How ABCL's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about ABCL from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 10 days ago · Oct 7
- AbCellera Biologics (Nasdaq:ABCL) - Aktienanalyse - Simply Wall St
- abcellera biologics inc
- AbCellera Biologics Inc. - AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
- Latest news about AbCellera Biologics Inc. - MarketScreener
- AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
ABCL research tape
115 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to ABCL.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries
ABCL — watch above $8.45
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet